Brain-derived neurotrophic factor (BDNF) is a critical neurotrophin that supports the survival, growth, and plasticity of neurons throughout the lifespan. BDNF and its signaling pathways are implicated in the pathogenesis of Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis, making it a key therapeutic target[@bdnfad2022, @bdngeneral2020].
BDNF is a member of the neurotrophin family, which also includes nerve growth factor (NGF), neurotrophin-3 (NT-3), and neurotrophin-4 (NT-4)[1]:
BDNF is expressed throughout the CNS:
BDNF signals through two receptor classes[@bdnfad2022, @bdngeneral2020]:
TrkB (Tropomyosin receptor kinase B)
p75^NTR (p75 neurotrophin receptor)
BDNF binding activates multiple downstream pathways[@bdnfad2022, @bdngeneral2020]:
PI3K/Akt pathway
Ras/ERK pathway
PLCγ pathway
p75^NTR can signal:
The downstream signaling cascades activated by BDNF receptors form an integrated network coordinating neuronal survival, plasticity, and function:
Multiple studies show BDNF deficits in AD:
The balance between pro-BDNF and mature BDNF represents a critical regulatory mechanism in neurodegeneration[2]:
BDNF-based therapies for AD include:
PD shows:
The dopaminergic system shows particular vulnerability to BDNF deficiency:
The relationship between alpha-synuclein and BDNF represents a critical interaction in PD pathogenesis:
BDNF is crucial in HD:
ALS shows complex BDNF involvement:
| Approach | Agent | Status |
|---|---|---|
| Recombinant BDNF | BDNF protein | Clinical trial (ALS) |
| TrkB agonists | 7,8-DHF | Preclinical |
| Small molecules | Amitriptyline (↑BDNF) | Clinical use |
| Exercise mimetics | N/A | Research |
BDNF as a biomarker:
The relationship between amyloid-beta (Aβ) pathology and BDNF signaling represents a critical nexus in Alzheimer's disease pathogenesis. Aβ oligomers directly impair BDNF signaling through multiple mechanisms[3]:
The accumulation of Aβ creates a feedforward loop where BDNF deficiency promotes greater vulnerability to Aβ toxicity, while Aβ accumulation further suppresses BDNF expression and signaling. This bidirectional relationship suggests that restoring BDNF signaling could potentially interrupt the progressive cascade of synaptic loss in AD.
The interaction between tau pathology and BDNF represents another critical axis of dysfunction in AD. Hyperphosphorylated tau disrupts BDNF signaling through several mechanisms:
The reciprocal relationship between BDNF and tau creates additional therapeutic complexity, as interventions targeting one pathway may have unintended consequences on the other.
Chronic neuroinflammation represents a major suppressor of BDNF expression in neurodegenerative diseases. Microglial activation and pro-inflammatory cytokines directly impact BDNF biology:
Interestingly, microglia can also serve as a source of BDNF in certain contexts. The microglial BDNF response appears to be context-dependent, with beneficial effects in early disease stages potentially shifting to detrimental outcomes as chronic inflammation progresses. This suggests that timing and modulation of microglial activation states may be critical for BDNF-based therapeutic interventions.
The BDNF Val66Met polymorphism represents a well-studied genetic variant that influences both BDNF function and neurodegenerative disease risk[3:1]:
The polymorphism's effects highlight the importance of BDNF signaling efficiency in maintaining cognitive reserve and neuronal resilience across the lifespan.
The circadian regulation of BDNF represents an emerging area of research with implications for neurodegenerative disease:
The intimate connection between sleep, circadian function, and BDNF suggests that optimizing sleep hygiene and circadian alignment may support endogenous BDNF production.
BDNF gene therapy using viral vectors represents one of the most advanced therapeutic approaches:
| Vector | Promoter | Target | Stage |
|---|---|---|---|
| AAV2 | Synapsin | Neurons | Phase I |
| AAV9 | GFAP | Astrocytes | Preclinical |
| AAVrh.10 | Mecp2 | Motor neurons | Preclinical |
The choice of promoter and serotype significantly influences BDNF expression patterns and therapeutic outcomes.
Small molecule TrkB agonists offer an alternative to direct BDNF delivery[4]:
Novel delivery systems using nanoparticles offer promising approaches for CNS BDNF delivery[1:1]:
The measurement of BDNF in peripheral compartments offers biomarker potential for neurodegenerative disease monitoring[1:2]:
Recent advances in BDNF and neurodegeneration:
BDNF Therapy: New delivery methods for BDNF show promise in preclinical models of Alzheimer's and Parkinson's (Nagahara & Tuszynski, 2024).
TrkB Agonists: Small molecule TrkB agonists are in development for treating synaptic dysfunction in AD (Huang et al., 2025).
Exercise and BDNF: Studies continue to elucidate exercise-induced BDNF release and its therapeutic potential (Cotman et al., 2024).
Aerobic exercise represents the most robust physiological stimulus for BDNF production in the central nervous system[5]. The mechanisms underlying exercise-induced BDNF elevation provide insights into potential therapeutic applications.
| Exercise Type | Intensity | Frequency | Expected BDNF Effect |
|---|---|---|---|
| Aerobic | Moderate | 3-5x/week | Significant increase |
| HIIT | High | 3x/week | Moderate increase |
| Resistance | Moderate | 2-3x/week | Modest increase |
Clinical studies demonstrate that exercise interventions increase peripheral BDNF in patients with AD and PD, with corresponding improvements in cognitive and motor function. However, the translation from peripheral BDNF increases to CNS functional benefits remains an active area of investigation.
Brain-derived neurotrophic factor in Alzheimer's disease and its pharmaceutical potential. Translational Neurodegeneration. 2022. ↩︎ ↩︎ ↩︎
Pro-BDNF and mature BDNF in neurodegeneration: opposite effects. Cell Death and Disease. 2021. ↩︎
Apoptosis in Alzheimer's disease: insight into the signaling pathways and therapeutic avenues. Apoptosis. 2023. ↩︎ ↩︎
TrkB agonists for neurodegenerative diseases: preclinical and clinical progress. Nature Reviews Drug Discovery. 2023. ↩︎
Exercise-induced BDNF and cognitive function in aging and AD. Progress in Neurobiology. 2022. ↩︎